Anabios Corp
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- SAM.gov registration date
- Website
- anabios.com
- Founded
- 2009
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Consumer Discretionary
- Consumer Services
- Diversified Consumer Services
- Specialized Consumer Services
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Vala Sciences Inc. | San Diego, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Eurofins Discoverx LLC | Fremont, CA | 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) |
| Regulonix LLC | Gainesville, FL | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Biotesting Division | Plainsboro Center, NJ | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Lena Biosciences, Inc. | Atlanta, GA | — |
About the company
Anabios Corporation is a translational research company that provides human-based testing services and data to support the development of promising new therapies. Through federal contracts and grants, the company generates predictive data on drug effects and safety using human primary cell models.
Anabios has provided human dorsal root ganglia samples, human ventricular cardiomyocyte testing services, and other specialized bioassay services to federal agencies including the NIH, FDA, and NCATS. These services, provided both as a prime contractor and subcontractor, support federal research programs related to pain, addiction, cardiology, and drug development. Services are provided on a fee-for-service basis without any small business set-aside designations.
Anabios has also received federal grants to develop new research platforms and biomarkers using its human primary cell technologies. Grants were awarded by the NINDS, NIDA, and FDA to advance translational pain drug screening methods, cardiac safety testing protocols, and proarrhythmia risk biomarkers based on human cardiomyocyte contractility. These programs aim to improve the predictive value of preclinical data and the translational success of new pain and cardiac therapies.
Additionally, Anabios holds an IDIQ contract from the FDA to provide electrophysiology and contractility testing services on human ventricular cardiomyocytes. This $500,000 IDIQ contract covers specialized bioassay services over a one-year period to support the FDA's evaluation of drug effects on cardiac function. Task orders under this contract vehicle are awarded on a firm fixed price basis.
Quick answers
Is Anabios Corp registered in SAM.gov?
Anabios Corp's SAM.gov registration expired on September 17, 2025.
What is Anabios Corp's CAGE code?
Anabios Corp's CAGE code is 631Z6, and its Unique Entity ID (UEI) is P3N4G7B5SRA7.
What is Anabios Corp's most recent federal award?
Anabios Corp's most recent federal grant award is Development of a novel analgesic for mixed inflammatory and neuropathic pain states (R44NS119036), from National Institute of Neurological Disorders and Stroke (NIH), on September 15, 2021.
On GovTribe
See Anabios Corp's full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors